The cognitive neuroscience of ketamine in major depression
Brain · 03.10.2025 · 148 (10) · 3496-3504
DOI: 10.1093/brain/awaf242 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 30.06.2025. Verfasst von Sara Costi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK. Hauptthemen laut MEDLINE: Ketamine, Major Depressive Disorder, Antidepressive Agents, Cognitive Neuroscience. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council MICA, National Institute for Health, Care Research.
Themen: Depression
Abstract (Originalsprache)
Ketamine’s potential as a rapid-acting antidepressant was first identified in 2000, despite its long-standing use as an anaesthetic agent. Clinically, ketamine alleviates depressive symptoms, including the difficult-to-treat symptom of anhedonia, within hours, with the effects of a single dose lasting for days. Since then, research has focused on uncovering the mechanisms underlying its rapid antidepressant effects in both humans and animal models. While its molecular and cellular effects have been extensively characterized, its impact on cognitive and neuropsychological mechanisms—potential mediators of its clinical efficacy—remains an area of ongoing investigation. Preclinical studies suggest that ketamine rapidly influences the lateral habenula (involved in punishment processing) and fronto-striatal (reward) systems, reverses negative affective biases in established memories, and promotes long-term stress resilience. Translating these findings to human models is crucial, and emerging evidence suggests that ketamine engages similar mechanisms in healthy volunteer and patient groups. However, its clinical application is constrained by acute side effects and an unknown long-term safety profile. Further research into ketamine’s mechanisms of action will be essential to inform the development of novel, safer and more accessible rapid-acting antidepressants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.
- Oxford Health Foundation Trust, Warneford Hospital, Oxford OX3 7JX, UK.
- Depression and Anxiety Center for Discovery and Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA.
Förderung
- Medical Research Council MICA
- National Institute for Health
- Care Research
- NIHR
- Oxford Health
- Biomedical Research Centre
- BRC
- Department of Health and Social Care
Zitieren
APA
Costi, S., Wigg, C., Pulcu, E., Murphy, S. E., & Harmer, C. J. (2025). The cognitive neuroscience of ketamine in major depression. Brain, 148(10), 3496-3504. https://doi.org/10.1093/brain/awaf242
Vancouver
Costi S, Wigg C, Pulcu E, Murphy SE, Harmer CJ. The cognitive neuroscience of ketamine in major depression. Brain. 2025;148(10):3496-3504. doi:10.1093/brain/awaf242
BibTeX
@article{Costi2025,
author = {Costi, Sara and Wigg, Chloe and Pulcu, Erdem and Murphy, Susannah E and Harmer, Catherine J},
title = {The cognitive neuroscience of ketamine in major depression},
journal = {Brain},
year = {2025},
volume = {148},
number = {10},
pages = {3496--3504},
doi = {10.1093/brain/awaf242}
}
EUVIMED